Rovadicitinib

DB21747InvestigationalSmall molecule

Rovadicitinib is under investigation in clinical trials NCT06682169 and NCT06300320 for the treatment of Chronic Graft-versus-host Disease.

Mechanism: Pharmacologically active on Tyrosine-protein kinase JAK2, Tyrosine-protein kinase JAK1, and Rho-associated protein kinase 2
Curator reviewed
Formula / weight: C₁₇H₁₉N₇ · 321.388 g/mol (avg)
Code names: TQ05105

Resolves to

Compound

Structure

InChIKeyZGENDZDSLYKCSI-CQSZACIVSA-NSMILESNC1=NN(C=C1C1=C2C=CNC2=NC=N1)[C@H](CC#N)C1CCCC1

Targets

What you can answer from here — as of September 13, 2026

4Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

14Clinical trialsPhase, status and sponsor resolved per trial

12+ReferencesStructured and connected to the statements they support

Which drugs share a target with Rovadicitinib, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.